We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+25.06%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.55B
AUM Growth
+$50.7M
(+3.4%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-15.23%
Top 10 Holdings %
Top 10 Hldgs %
80.86%
Holding
37
New
7
Increased
10
Reduced
8
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$94.8M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$56M |
| 3 |
Vaxcyte
PCVX
|
+$28.4M |
| 4 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$14.6M |
| 5 |
AKUS
Akouos Inc
AKUS
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Stock Market ETF
VTI
|
+$401M |
| 2 |
Cable One
CABO
|
+$31M |
| 3 |
Akebia Therapeutics
AKBA
|
+$14.5M |
| 4 |
Apple
AAPL
|
+$9.11M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$7.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.51% |
| 2 | Technology | 8.91% |
| 3 | Communication Services | 6.56% |
| 4 | Financials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vanguard Total Stock Market ETF
VTI
$656B
| $481M | 31.03% |
3,070,400
-2,720,000
| -47% | -$401M |
|
|
2
Apple
AAPL
$4.99T
| $138M | 8.91% |
1,512,904
-117,520
| -7% | -$9.11M |
|
3
Inogen
INGN
$174M
| $126M | 8.14% |
3,549,321
| – | – |
|
|
4
Cable One
CABO
$249M
| $102M | 6.56% |
57,291
-17,304
| -23% | -$31M |
|
5
Brookfield
BN
$104B
| $101M | 6.52% |
5,738,048
-1
| -0% | -$18 |
|
|
6
Medtronic
MDT
$111B
| $90.6M | 5.85% |
+988,136
| New | +$94.8M |
|
|
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $71.6M | 4.62% |
2,645,446
| – | – |
|
|
CTLT
8
DELISTED
CATALENT, INC.
CTLT
| $60.5M | 3.9% |
+824,739
| New | +$56M |
|
9
Mirum Pharmaceuticals
MIRM
$6.84B
| $47.6M | 3.07% |
2,445,147
| – | – |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $35M | 2.26% |
2,320,026
| – | – |
|
|
11
Vaxcyte
PCVX
$7.88B
| $27.9M | 1.8% |
+881,898
| New | +$28.4M |
|
|
12
Akebia Therapeutics
AKBA
$341M
| $27M | 1.74% |
1,987,506
-1,405,533
| -41% | -$14.5M |
|
|
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $24.3M | 1.57% |
3,409,021
| – | – |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $20M | 1.29% |
256,767
+22,500
| +10% | +$1.52M |
|
|
SPNE
15
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $18.7M | 1.21% |
1,790,431
+75,000
| +4% | +$767K |
|
|
FLXN
16
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $18.5M | 1.19% |
+1,403,370
| New | +$14.6M |
|
17
SI-BONE Inc
SIBN
$795M
| $15.8M | 1.02% |
989,827
+18,437
| +2% | +$291K |
|
18
Protagonist Therapeutics
PTGX
$8.8B
| $14.6M | 0.94% |
824,169
+126,270
| +18% | +$1.58M |
|
|
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $13.1M | 0.85% |
437,131
+268,750
| +160% | +$9.68M |
|
20
Spero Therapeutics
SPRO
$69.5M
| $12.6M | 0.81% |
931,099
| – | – |
|
|
AERI
21
DELISTED
Aerie Pharmaceuticals
AERI
| $11.9M | 0.77% |
807,656
+56,682
| +8% | +$838K |
|
22
Insmed
INSM
$22.6B
| $11.8M | 0.76% |
+430,107
| New | +$10.2M |
|
|
AKUS
23
DELISTED
Akouos Inc
AKUS
| $10.5M | 0.68% |
+467,786
| New | +$10.4M |
|
|
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
| $8.8M | 0.57% |
325,814
+102,630
| +46% | +$2.83M |
|
25
Corvus Pharmaceuticals
CRVS
$1.12B
| $7.96M | 0.51% |
2,927,560
| – | – |
|
Similar funds
HCA
GX
MP
FLII
CA
IC
WTA
CCA
Novo Holdings A/S's Q2 2020 Portfolio in Review
As of Q2 2020, Novo Holdings A/S held 37 positions worth $1.55B, up 3.4% from $1.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Novo Holdings A/S withdrew a net $236M in Q2 2020, closing 2 positions and reducing 8 holdings. Its most notable exit was MyoKardia, Inc. Common Stock, an estimated $7.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Novo Holdings A/S opened a new position in Medtronic worth $90.6M.
- Novo Holdings A/S's largest Q2 2020 buy was Medtronic: 988,136 shares worth $90.6M.
- Novo Holdings A/S added most to Constellation Pharmaceuticals, Inc. in Q2 2020, an estimated $9.68M increase.
- Novo Holdings A/S's biggest Q2 2020 reduction was Vanguard Total Stock Market ETF, cutting an estimated $401M.
- Novo Holdings A/S fully exited MyoKardia, Inc. Common Stock in Q2 2020, selling an estimated $7.12M.
- Novo Holdings A/S's ten largest holdings make up 81% of its $1.55B portfolio in Q2 2020.
- Novo Holdings A/S opened 7 new positions and closed 2 in Q2 2020.
- Novo Holdings A/S's portfolio value rose 3.4% quarter-over-quarter to $1.55B.
Based on Novo Holdings A/S's 13F filing for Q2 2020, filed 14 Aug 2020.